HISTOPLASMA DNA PCR TEST

  • Test Code

    403

  • CPT Code

    87798 x1

  • Clinical Significance

    Histoplasma capsulatum (also known as Ajellomyces capsulatum) is a dimorphic fungus which is the causative agent of Histoplasmosis, which primarily affects the lungs. Most infections are asymptomatic, but the acute phase may present mild respiratory symptoms. Chronic histoplasmosis may progress to disseminated disease, which can be fatal, especially in immunocompromised individuals (e.g., HIV patients), though cases in healthy individuals have also been reported. Central nervous system (CNS) involvement may occur with or without disseminated disease and can present as meningitis or other neurologic manifestations; therefore, detection of Histoplasma DNA in cerebrospinal fluid (CSF) may support evaluation for CNS histoplasmosis when interpreted in conjunction with clinical findings and other laboratory results. Histoplasmosis is endemic to parts of the Americas, Asia, and Africa, but can occur elsewhere. The gold standard for diagnosis of histoplasmosis remains isolation of the organisms in culture. Although sensitive, recovery in culture and subsequent identification may require days to weeks. This polymerase chain reaction assay can provide rapid and specific detection and differentiation of Histoplasma capsulatum directly from clinical specimens.

  • Methodology

    Qualitative Real-Time PCR (Polymerase Chain Reaction)

  • Limitations

    Specimens positive for Paracoccidioides brasiliensis, Aspergillus flavus, Aspergillus nidulans, and Aspergillus niger may cross react and test positive. When tested in cultures of 108 – 109 organisms/mL, cross-reactions occurred with Paracoccidioides brasiliensis, Aspergillus flavus, Aspergillus nidulans, and Aspergillus niger.

    Fluconazole may interfere with assay sensitivity. When tested with Fluconazole at 7.0 ug/ mL in CSF specimens, interference occurred that lead to false negative test results.

  • Specimen Collection

    BAL, CSF, tracheal aspirate*, or bronchial wash* in a sterile leak-proof container.

    * Reported with a rare specimen comment applied.

  • Minimum Specimen Requirements

    BAL, CSF, tracheal aspirate*, or bronchial wash* = 0.5 mL

    * Reported with a rare specimen comment applied.

  • Specimen Stability

    BAL

    • Room Temperature: 30 days
    • Refrigerated: 30 days
    • Frozen: 30 days

    CSF

    • Refrigerated: 5 days
    • Frozen: 30 days
  • Specimen Rejection
    • Sputum and all other non-respiratory samples.
    • Two unique patient identifiers are required on the specimen container.
    • Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.
    • Grossly bloody CSF specimens will be rejected.
  • Transport Temperature
    • Refrigerated
    • Frozen
  • Shipping

    Samples may be shipped on dry ice or frozen ice packs

  • Turnaround Time

    Same Day

  • Reference Range

    Not detected

  • Interpretative Information

    PCR testing should be done in conjunction with appropriate microbiology, antigen, and/or antibody testing. A positive PCR result indicates the DNA was detected in the sample and that organism could be the cause of disease.  Some organisms (molds and yeasts) can be commensals (or colonizers) and found in non-sterile locations such as the respiratory, GI, and urinary systems – without causing disease.  A negative result indicates DNA was not detected in the sample but does not rule-out that organism as the cause of disease. All results should be interpreted considering the full clinical picture.

  • Additional Information

    This test was developed, and its analytical performance characteristics were determined by MiraVista Diagnostics. It has not been cleared or approved by the FDA; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

  • Accepted Specimen Types
    • Bronchoalveolar Lavage (BAL)
    • Cerebral Spinal Fluid (CSF)

* New positives may require confirmation.

** Turnaround times are provided as ranges, and may vary depending on daily testing volumes and specimen type.

*** Test set-up: Samples received by 10:30 AM are eligible for same-day testing. Same-day testing is not guaranteed and may vary based on daily test volume, sample receipt time, testing schedules, and sample type. Some samples may require pretreatment and/or confirmatory testing, which can extend turnaround time (TAT).

**** Two unique patient identifiers are required on specimen containers. 

***** Specimens with particulate matter or viscosity that would not allow the specimen to be pipetted will be rejected.

CONTACT US

Only Available at MiraVista Diagnostics: MycoMEIA® Aspergillus Galf Urine EIA
MiraVista Diagnostics now offers MycoMEIA® Aspergillus Galf Urine EIA, a urine-based antigen assay that complements serum galactomannan (GM) testing and may improve diagnostic confidence for invasive aspergillosis (IA).

Close Welcome Bar